Ocugen, Inc. (OCGN)

NCM – Real vaqt narxi. Valyuta: USD

1.47

-0.01 (-0.68%)

Yopilishda: May 12, 2026, 4:00 PM EDT

1.48

+0.01 (0.68%)

Bozor oldidan: May 13, 2026, 9:14 AM EDT

08.05.2026

Ocugen (OCGN) Upgraded to Buy: Here's Why

Ocugen (OCGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

06.05.2026

OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook

Ocugen swings to a wider Q1 loss as costs climb, but pipeline milestones and gene therapy data keep its long-term plans on track.

05.05.2026

Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript

05.05.2026

Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates

Ocugen (OCGN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.05 per share a year ago.

05.05.2026

Ocugen Provides Business Update with First Quarter 2026 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p 30% reduction in Iesion growth compared to control, with a favorable safety and tolerability profile Allows robust registrational Phase 3 trial design, a potential combined U.S./EU trial with 300 subjects, with adaptive design powered at over 95% Trial enrollment complete for OCU400 for retinitis pigmentosa (RP) and OCU410ST for Stargardt disease registration trials, and on target to complete two Biologics License Application (BLA) submissions by 2027 The closing of a private offering of $115 million aggregate principal amount ($130 million if overallotment is exercised) of 6.75% convertible senior notes due 2034, with a conversion premium of 45%, is expected to extend cash runway into 2028, subject to customary closing conditions The Company expects to utilize $32.7 million of net proceeds from the Notes to retire the Avenue debt (12.5% interest rate) MALVERN, Pa.

05.05.2026

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ocugen also granted the initial purchaser of the notes a 13-day option to purchase up to an additional $15 million aggregate principal amount of the notes. The sale of the notes to the initial purchaser is expected to close on May 7, 2026, subject to customary closing conditions, and is expected to result in approximately $99.5 million (or approximately $112.6 million if the initial purchaser exercises its option to purchase additional notes in full) in net proceeds to Ocugen after deducting the initial purchaser's discount and estimated offering expenses payable by Ocugen.

04.05.2026

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

MALVERN, Pa., May 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced its intention to offer, subject to market conditions and other factors, $115 million aggregate principal amount of Convertible Senior Notes due 2034 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ocugen also expects to grant the initial purchaser of the notes a 13-day option to purchase up to an additional $15 million aggregate principal amount of the notes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Videolar

No Data

There is no data to display

Press-relizlar

05.05.2026

Ocugen Provides Business Update with First Quarter 2026 Financial Results

05.05.2026

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

04.05.2026

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

01.04.2026

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

MALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate developed for all Stargardt disease (ABCA4-associated retinopathies).

Ocugen, Inc. (OCGN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ocugen, Inc. (OCGN)

Ocugen (OCGN) Upgraded to Buy: Here's Why

OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook

Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript

Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates

Ocugen Provides Business Update with First Quarter 2026 Financial Results

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

Videolar

No Data

Press-relizlar

Ocugen Provides Business Update with First Quarter 2026 Financial Results

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Ocugen (OCGN) Upgraded to Buy: Here's Why

OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook

Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript

Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates

Ocugen Provides Business Update with First Quarter 2026 Financial Results

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

Videolar

No Data

Press-relizlar

Ocugen Provides Business Update with First Quarter 2026 Financial Results

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Search stocks

Ocugen, Inc. (OCGN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ocugen, Inc. (OCGN)

Ocugen (OCGN) Upgraded to Buy: Here's Why

OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook

Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript

Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates

Ocugen Provides Business Update with First Quarter 2026 Financial Results

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

Videolar

No Data

Press-relizlar

Ocugen Provides Business Update with First Quarter 2026 Financial Results

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Ocugen (OCGN) Upgraded to Buy: Here's Why

OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook

Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript

Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates

Ocugen Provides Business Update with First Quarter 2026 Financial Results

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

Videolar

No Data

Press-relizlar

Ocugen Provides Business Update with First Quarter 2026 Financial Results

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease